The Cardioprotective Effects of Empagliflozin with and Without ACE Inhibition in Chemotherapy-Induced Cardiotoxicity
: Prophylactic administration of EMPA mitigated adverse cardiovascular remodeling in a chronic in vivo model of DOX + TRZ-mediated cardiotoxicity.
Authors
- James A. Thliveris (ORCID: https://orcid.org/0000-0002-1896-9878)
- Allison Ledingham
- Sara M. Telles-Langdon
- Davinder S. Jassal (ORCID: https://orcid.org/0000-0002-3639-9047)
- Lana Mackic
- Paris R. Haasbeek
- Danielle Desautels
- T. Rozovsky
- David Y. C. Cheung
- Lauren Castagna
- Adrian Siapno
- Joerg Herrmann
- Leah Schwartz
Institutions
- Mayo Clinic in Arizona (US)
- University of Manitoba (CA)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3390/biomedicines14040903
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- CancerCare Manitoba Foundation